ITGA6 and breast carcinoma: In addition, an early phase I clinical study (NCT04289532) employed 99mTc-RWY, a radiotracer for ITGA6-targeting (RWY peptide), to perform single-photon emission computed tomography imaging in breast cancer patients, helping to predict overall survival and prognosis [12].